


Patient Name	LastName, FirstName	Treatment Date	15-Dec-2019	ProtaGene ID	CLIA20010101BGW_01
MRN	999999999	Collection Date	16-Dec-2019	Visit#	1
DOB	01' 9	Received Date	01-Jan-2020	Treatment	Treatment
Gender	M	Analysis Date	01-Feb-2020	Facility Sample ID	19-12-000001
Diagnosis	Ох	Approval Date	15-Feb-2020	Facility Name	Facility Name
Referring Physician	ring, MD	Sample Type	Blood		

## **EGRATION SITE (IS) ANALYSIS SUMMARY REPORT**

**Test Summary:** IS analysis as the Afety evaluation to monitor for potential oncogenesis determined IS locations in DNA of the provided sample and dir relative abundance as clonality measurement by S-EPTS/LM-PCR, next-generation sequencing, and bioinfor affective sis.

Result: IS profile is presented as relation on tribing of the ten most abundant IS.



**Comments:** While increasing IS contribution may be associated with an increased river a malique ancy, it will not a priori result in a malignancy. Therefore, regular IS testing and timely trigger of enhancements and increased river a malique ancy, it will not a priori result in a malignancy. Therefore, regular IS testing and timely trigger of enhancements and increased river a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy, it will not a priori result in a malique ancy and result in a malique ancy ancy and result in a malique ancy ancy and result in a malique ancy and result in a malique

Note that sequencing reads mapping to multiple locations in the reference genome have been to differ analysis. Frequency of the high contributing IS were not substantially changed. IS test results should be interpreted in consultation with a qualified licensed to although a ctioner.

Approval: Result was reviewed and approved by the Laboratory Director, Pertti T.K. Toivola, PhD.

**Disclaimer**: Integration Site Analysis (ISA) test has not been reviewed, approved, or cleared by the FDA, nor is such approval required. Test results are for clinical purposes and should not be considered investigational or for research. The characteristics of the ISA test have been determined and verified by ProtaGene, a CLIA registered laboratory approved to perform high complexity tests.